热带病与公共卫生杂志

抽象的

Sickle Cell Disease (SCD) and COVID-19: Case Series

Awaji Q. Al-Naami, Liaqat A. Khan, Faisal I. Zaidan, Hussam M.Halawi, Laila E.Asiri, Taher A.Suamili, Amal A. Qaisi, Turki M.Darweesh, Ibrahim A Al-Naami

The ongoing pandemic of COVID-19 that started in the Hubei province of China in late December 2019, caused by severe acute respiratory syndrome corona virus-2 (SARS CoV-2). Globally millions affected by the disease so far. The risk of COVID-19 severity and its complications increases with age and other comorbidities. The course of SARS-CoV-2 infection or its related complications has yet to be established in patients with sickle cell disease (SCD), once more evidence is available. It is clear from the available data that the course of COVID-19 in patients with SCD is mild to moderate, seldom severe, and rarely fatal. Herein we report three known cases of SCD with confirmed COVID-19, in whom the course of the disease was mild to moderate and uncomplicated with uneventful recoveries.